Melflufen Open to Select Adults With Advanced Multiple Myeloma in US
Oncopeptides has formally opened sEAPort, its open-label expanded access program allowing adults with…
Steve Bryson, PhD, science writer — 
Articles by Steve Bryson
CHMP Favors Darzalex Faspro in Treating Patients in EU
Janssen‘s new under-the-skin formulation of daratumumab, called Darzalex Faspro, has been recommended for approval…
Gains in 5-Year Survival with Stem Cell Transplant Evident Since Late ’90s
The long-term survival of people with multiple myeloma following autologous stem cell transplant has steadily improved since 1997…
New CAR T-cell Therapy Shows Early Promise Against Multiple Myeloma in Lab Study
A new CAR T-cell therapy  for people with multiple myeloma has been successfully created and tested in…
Pivotal DREAMM-2 Trial Supports Belantamab Mafodotin’s Use for Heavily-treated Multiple Myeloma
Treatment with belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, resulted in clinically meaningful responses in about one-third of hard-to-treat multiple…
Top 10 Multiple Myeloma Stories of 2019
Myeloma Research News brought you daily coverage of important findings, treatment developments, clinical trials, and other events related to multiple myeloma…